Is Angiotensin I Inactivated?
Yes, angiotensin I is inactivated through multiple enzymatic pathways, though its primary fate is conversion to angiotensin II rather than direct inactivation.
Primary Metabolic Pathways
Angiotensin I undergoes two main metabolic routes:
Conversion to Angiotensin II (Activation)
- Angiotensin-converting enzyme (ACE) cleaves two amino acids from the C-terminal end of angiotensin I (a decapeptide) to form angiotensin II (an octapeptide) 1
- This is the dominant pathway under physiological conditions
- ACE is highly concentrated in the lungs, kidneys, and vascular endothelium 2
- Alternative enzymes like chymase can also generate angiotensin II independently of ACE 3
Direct Inactivation Pathways
Angiotensin I can be inactivated without conversion to angiotensin II through:
- Neutral endopeptidase 24.11 cleaves the C-terminal tripeptide from angiotensin I 4
- Prolyl endopeptidase can also inactivate angiotensin I 4
- ACE2 (angiotensin-converting enzyme 2) cleaves leucine from angiotensin I to form angiotensin-(1-9), which has modest biological activity 1
- Neprilysin converts angiotensin I directly to angiotensin-(1-7) 3, 1
- Aminopeptidases and carboxypeptidases contribute to degradation 5
Clinical Significance
During ACE inhibitor therapy, a critical point emerges: while ACE inhibition blocks angiotensin II formation, angiotensin I does not accumulate because alternative degradation pathways remain active 6. Studies using cultured endothelial cells and isolated perfused rabbit aorta demonstrated that when ACE is inhibited, angiotensin I is directly degraded to small peptides rather than being converted to angiotensin II 6.
Tissue-Specific Metabolism
The extent of angiotensin I conversion versus inactivation varies by vascular bed 7:
- Pulmonary circulation: Greatest proportion of conversion (primary site)
- Mesenteric bed: 45.7% conversion
- Renal circulation: Only 8.9% conversion (least proportion) 7
Key Takeaway
Angiotensin I is not simply "inactivated"—it exists at a metabolic crossroads. The majority is converted to the active peptide angiotensin II via ACE, but multiple inactivation pathways exist that degrade it to inactive fragments. The balance between activation and inactivation is tissue-dependent and can be therapeutically manipulated with ACE inhibitors, which shift metabolism toward direct inactivation rather than angiotensin II formation 8, 9.